Free Trial

Lyell Immunopharma (LYEL) SEC Filings & 10K Form

Lyell Immunopharma logo
$9.52 -0.01 (-0.10%)
Closing price 04:00 PM Eastern
Extended Trading
$9.52 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Lyell Immunopharma SEC Filings

DateFilerForm TypeView
06/26/2025
3:07 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2025
7:49 AM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2025
4:48 PM
Bachleda Mark (Reporting)
Lyell Immunopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2025
4:38 PM
Lyell Immunopharma (Issuer)
Shook David (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/11/2025
4:40 PM
Lyell Immunopharma (Issuer)
Meltz Mark A (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/11/2025
4:42 PM
Bachleda Mark (Reporting)
Lyell Immunopharma (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
06/11/2025
4:45 PM
Lyell Immunopharma (Issuer)
Shook David (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2025
4:47 PM
Lyell Immunopharma (Issuer)
Meltz Mark A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025
3:23 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/19/2025
5:41 PM
Lyell Immunopharma (Issuer)
Ramachandra Sumant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025
5:43 PM
Lyell Immunopharma (Issuer)
NABEL ELIZABETH G (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025
5:45 PM
BRAWLEY OTIS W (Reporting)
Lyell Immunopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025
5:47 PM
FRIEDMAN CATHY (Reporting)
Lyell Immunopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025
5:48 PM
Lyell Immunopharma (Issuer)
RIEFLIN WILLIAM JL (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025
5:50 PM
Klausner Richard (Reporting)
Lyell Immunopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2025
3:39 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/13/2025
3:41 PM
Lyell Immunopharma (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/10/2025
3:55 PM
Lyell Immunopharma (Filer)
Form PRE 14A
04/02/2025
2:46 PM
BRAWLEY OTIS W (Reporting)
Lyell Immunopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2025
4:01 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2025
5:46 PM
Lyell Immunopharma (Issuer)
Ramachandra Sumant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2025
7:07 PM
Klausner Richard (Reporting)
Lyell Immunopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2025
6:01 PM
Lyell Immunopharma (Issuer)
Newton Charles W. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2025
5:59 PM
Lyell Immunopharma (Issuer)
Seely Lynn (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2025
3:52 PM
Lyell Immunopharma (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/26/2025
6:27 PM
Lee Gary K. (Reporting)
Lyell Immunopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2025
6:29 PM
Lyell Immunopharma (Issuer)
Newton Charles W. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2025
6:31 PM
Hill Stephen J. (Reporting)
Lyell Immunopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2025
6:33 PM
Lyell Immunopharma (Issuer)
Seely Lynn (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2025
6:36 PM
Lang Matthew (Reporting)
Lyell Immunopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2025
12:23 PM
BlackRock, Inc. (Filed by)
Lyell Immunopharma (Subject)
Form SCHEDULE 13G/A
01/24/2025
3:39 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/10/2025
8:10 AM
Lyell Immunopharma (Filer)
Form 8-K/A
12/09/2024
8:03 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/09/2024
7:39 AM
Lyell Immunopharma (Filer)
Form 424B5
12/05/2024
11:15 PM
Lyell Immunopharma (Filer)
Form EFFECT
11/29/2024
3:19 PM
Lyell Immunopharma (Filer)
Form S-3
Registration statement under Securities Act of 1933  
11/26/2024
3:05 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2024
12:30 PM
Lyell Immunopharma (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
11/01/2024
3:54 PM
Lyell Immunopharma (Issuer)
Ramachandra Sumant (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/01/2024
3:56 PM
Lyell Immunopharma (Issuer)
Ramachandra Sumant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
[No Brainer Gold Play]: “Show me a better investment.” (Ad)

A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.

Click here to get Garrett’s Top Four picks now.
10/31/2024
5:00 PM
Foresite Capital Fund IV, L.P. (Filed by)
Lyell Immunopharma (Subject)
Form SC 13G
10/31/2024
3:45 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2024
3:06 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:LYEL) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners